Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
NCT ID: NCT00638144
Last Updated: 2015-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2008-02-29
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution.
NCT00213707
Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
NCT00867243
Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C
NCT01428700
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation
NCT00701272
Interest of the Donor-specific Antibodies After Liver Transplantation
NCT03238443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
patients with resolved infection
No interventions assigned to this group
2
chronically infected patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Resolved HCV infection ( HCV RNA negative since more then 6 months ) -HCV chronically infected ( RNA positive )
* Anti- HCV antibodies positive
* Volunteers and informed patients
Exclusion Criteria
* HBV or HIV infection
* Pregnancy
* Breast feeding
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michel DOFFOEL, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU Strasbourg
Albert FARADJI, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU Strasbourg
Philippe WOLF, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU Strasbourg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Hépato-Gastro-Entérologie - Hôpital Civil
Strasbourg, , France
Service d'Hématologie et Oncologie - Hôpital de Hautepierre
Strasbourg, , France
Service de Chirurgie Générale et Transplantation Multiorganes - Hôpital de Hautepierre
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.